Testing guselkumab to improve Crohn's disease control
Treatments studied
Part of Digestive system clinical trials.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Crohn's disease
- You are 18 years or older
- You have active Crohn's symptoms right now (abdominal pain or frequent bowel movements) with high inflammation markers in stool
- You've had recent testing (endoscopy, MRI, or ultrasound) within 2 months showing active disease
- You have not previously taken anti-IL23 medications (a specific type of biologic)
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study looks at how well guselkumab works for people with moderate to severe Crohn's disease or ulcerative colitis when used as part of regular treatment. It gathers information from real patients to see how the drug performs outside of a research setting.
This study tests whether guselkumab (a targeted drug) can effectively treat Crohn's disease in the ileum (last part of the small intestine). You will have ultrasound scans and blood tests to measure your response, which may help find the right dose and monitor for bowel healing.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.